6340 Sequence Drive
216 articles with DexCom
Dexcom Schedules Fourth Quarter and Full Year 2018 Earnings Release and Conference Call for February 21, 2019 at 4:30 p.m. Eastern Time
DexCom (NASDAQ:DXCM) today announced that it plans to release its fourth quarter and full year 2018 financial results after market close on Thursday, February 21, 2019.
Dexcom Reports Record Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2018 and Provides Initial 2019 Outlook
For fiscal 2018, total preliminary, unaudited revenue is expected to exceed $1.025 billion, an increase of more than 42% over 2017.
DexCom, Inc. today announced that management will present an update on Dexcom at the following upcoming investor conference
Social media campaign #NoMoreFingerpricks raises funds and awareness for diabetes research
DexCom, Inc. announced today the pricing of its offering of $750.0 million aggregate principal amount of 0.75% Convertible Senior Notes due 2023 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended
DexCom, Inc. announced today that it intends to offer, subject to market conditions and other factors, $750 million aggregate principal amount of Convertible Senior Notes due 2023 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”).
DexCom, Inc. today announced that it will host an Investor Day on December 4, 2018 at the Laguna Cliffs Marriott in Dana Point, California. The event will include updates on the company’s innovation pipeline, business strategy, and long-term financial outlook.
Dexcom G6® Continuous Glucose Monitoring System Will Be Available to Medicare Beneficiaries with Diabetes in Early 2019
CMS approves coverage for Dexcom G6 CGM, the only CGM system recognized by Medicare that offers mobile device compatibility and no fingerstick calibration
Dexcom CGM data from Dexcom's cloud API is integrated into the Validic data connectivity platform – establishing one of the first multi-measure platforms to stream in-home clinical data directly into clinical workflows and systems.
DexCom Schedules Third Quarter 2018 Earnings Release and Conference Call for November 6, 2018 at 4:30 p.m. Eastern Time.
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its third quarter 2018 financial results after market close on Tuesday, November 6, 2018.
DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on DexCom at the following upcoming investor conference:
DexCom, Inc. (Nasdaq: DXCM) today reported its unaudited financial results as of and for the quarter ended June 30, 2018.
DexCom, Inc. today announced that management will present an update on DexCom at the following upcoming investor conference.
DexCom Schedules Second Quarter 2018 Earnings Release and Conference Call for August 1, 2018 at 4:30 p.m. Eastern Time.
DexCom, Inc. today announced that it plans to release its second quarter 2018 financial results after market close on Wednesday, August 1, 2018.
Revolutionary new CGM system eliminates routine fingersticks for people with diabetes and is nearly one-third smaller than previous generation
Dexcom G5 Continuous Glucose Monitoring System Now Available on Mobile, Smart Devices for Medicare Patients with Diabetes
Dexcom, Inc. announced the U.S. Centers for Medicare & Medicaid Services (CMS) is updating its policy on mobile device compatibility for the Dexcom G5® CGM System.
Federal Court Judge Awards AgaMatrix Attorneys' Fees While Admonishing Dexcom for "Bad Faith" Lawsuit
AgaMatrix, Inc. announced a prevailing outcome in a retaliatory patent infringement lawsuit brought by Dexcom, Inc. (NASDAQ: DXCM).
DexCom, Inc. reported its unaudited financial results as of and for the quarter ended March 31, 2018.
FDA Authorizes Marketing of the New Dexcom G6® CGM Eliminating Need for Fingerstick Blood Testing for People with Diabetes
DexCom, Inc. is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted a De Novo request for the Dexcom G6® CGM System, the newest generation of CGM for people with diabetes ages 2 and up.
FDA authorizes first fully interoperable continuous glucose monitoring system, streamlines review pathway for similar devices
The U.S. Food and Drug Administration today permitted marketing of the DexCom G6 integrated continuous glucose monitoring (iCGM) system for determining blood glucose (sugar) levels in children aged two and older and adults with diabetes.